 |
GC Biopharma |
[Alpha Biz= Reporter Kim Jisun] GC Biopharma and GC Cell’s U.S. affiliate, Artiva Biotherapeutics, have successfully entered the New York Stock Exchange. This achievement comes three years after a failed attempt to list in 2021.
According to the pharmaceutical industry on the 21st, Artiva was listed on the NASDAQ market on the 19th under the ticker symbol ARTV.
Artiva became the eleventh U.S. biotech company to go public this year. During this IPO, Artiva sold 13.92 million shares at $12 per share, raising $167 million (approximately 232.4 billion KRW) for research and development (R&D) expenses.
Artiva, founded in 2019 by GC Holdings and GC Cell in San Diego, specializes in developing cell therapies. As of the end of the first quarter, GC Holdings holds a 19.1% stake, and GC Cell holds 8.3%.
Artiva is developing chimeric antigen receptor (CAR)-NK cell therapies, which involve immune cells selectively attacking cancer cells.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
